Larvol Delta - Cingulate-Initiates-Phase-3-Study-of-Lead-Asset-CTx1301-Designed-as-a-True-Entire-ActiveDay-Treatment-for-ADHD

dexmethylphenidate tri-modal release (CTx-1301) - Cingulate Therap

https://www.globenewswire.com/news-release/2023/01/04/2582736/0/en/Cingulate-Initiates-Phase-3-Study-of-Lead-Asset-CTx-1301-Designed-as-a-True-Entire-Active-Day-Treatment-for-ADHD.html

Jan 4, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next